Flexion Therapeutics

Adam Muzikant, Ph.D., SVP, Business Development
Burlington, MA
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). Our first product, ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), is the first and only FDA-approved extended-release, intra-articular (in the joint) injection for OA knee pain. Our pipeline includes FX201, an intra-articular gene therapy candidate being developed for symptomatic relief and disease modification in patients with knee OA. FX201 is designed to durably stimulate the production of an anti-inflammatory protein, IL-1Ra, whenever inflammation is present in the joint. Enrollment in a Phase I clinical trial with FX201 in patients with knee OA began in Q1 2020. We are also developing FX301, a locally delivered NaV1.7 inhibitor formulated for extended release from a thermosensitive hydrogel, for control of post-surgical pain. FX301 is expected to enter clinical trials in 2021.

By using this website you agree to accept our Privacy Policy and Terms & Conditions